<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of gonadotroph and other clinically nonfunctioning adenomas</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of gonadotroph and other clinically nonfunctioning adenomas</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of gonadotroph and other clinically nonfunctioning adenomas</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gonadotroph adenomas are the most common pituitary macroadenomas, comprising approximately 80 percent of clinically nonfunctioning adenomas. These adenomas are difficult to identify because their secretory products usually do not cause a recognizable clinical syndrome and because they often secrete so inefficiently that serum concentrations of intact gonadotropins and their subunits are often only minimally abnormal or not abnormal at all. Consequently, they are typically not detected until they become sufficiently large to cause neurologic symptoms, most often impaired vision due to pressure on the optic chiasm. Clinically nonfunctioning or "silent" somatotroph and corticotroph adenomas are also being identified with increasing frequency.</p><p>The treatment of gonadotroph and other clinically nonfunctioning adenomas will be reviewed here. Their clinical manifestations and diagnosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/6627.html" rel="external">"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas"</a>.)</p><p class="headingAnchor" id="H3778196495"><span class="h1">INITIAL THERAPY: TRANSSPHENOIDAL SURGERY</span></p><p class="headingAnchor" id="H289096195"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Gonadotroph or other clinically nonfunctioning macroadenomas are typically diagnosed when they become large enough to cause a neurologic symptom (eg, visual loss, headache), a hormonal deficiency state, when an imaging study is performed for an unrelated reason, or, less commonly, because of hormonal hypersecretion.</p><p>For gonadotroph and other clinically nonfunctioning macroadenomas that are impairing vision, we recommend transsphenoidal surgery because it is the only treatment that can provide rapid relief of neurologic symptoms [<a href="#rid1">1,2</a>]. Transsphenoidal surgery reduces the size of the adenoma and its hormonal hypersecretion in more than 90 percent of cases and improves vision in approximately 80 percent [<a href="#rid3">3,4</a>].</p><p>For patients who have suprasellar extension but do not have neurologic symptoms, we discuss the risks of surgery versus the risks of waiting. For example, an adenoma that is markedly elevating the optic chiasm is very likely to begin to cause visual abnormalities in the next few years, yet some patients will choose to wait to undergo surgery until that occurs. Gonadotroph adenomas that are asymptomatic and not an immediate threat to vision may not require immediate surgery. (See <a class="local">'Asymptomatic adenomas'</a> below.)</p><p>Once identified, those with impaired vision should undergo transsphenoidal surgery. Transsphenoidal surgery should be considered for those at high risk for loss of vision (marked suprasellar extension).</p><p>The choice of transsphenoidal surgery procedure has evolved over time. The microscopic technique was introduced first, but the endoscopic technique is now considered the preferable approach because of better visualization. Transcranial surgery is virtually never the preferred approach. This issue is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/86683.html" rel="external">"Transsphenoidal surgery for pituitary adenomas and other sellar masses", section on 'Surgical techniques'</a>.)</p><p class="headingAnchor" id="H1408493741"><span class="h2">Goals</span><span class="headingEndMark"> — </span>The goals of treatment of a patient with a gonadotroph or clinically nonfunctioning adenoma include:</p><p class="bulletIndent1"><span class="glyph">●</span>Relief of visual impairment or other neurologic symptoms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduction of hormone hypersecretion if present</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Removal of as much of the adenoma as possible to avoid recurrence</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Replacement of hormonal deficiencies due to compression of nonadenomatous pituitary cells by the macroadenoma (see <a class="local">'Postoperative issues'</a> below)</p><p></p><p class="headingAnchor" id="H4156778169"><span class="h2">Preoperative preparation</span><span class="headingEndMark"> — </span>The most important aspects of the preoperative preparation for pituitary surgery include:</p><p class="bulletIndent1"><span class="glyph">●</span>Confirming the sellar lesion is a gonadotroph or other clinically nonfunctioning adenoma, which must be distinguished from a nonpituitary lesion in or near the sella, which might best be approached differently.</p><p></p><p class="bulletIndent1">Abnormalities that strongly suggest a gonadotroph adenoma include elevated basal serum concentrations of intact follicle-stimulating hormone (FSH) and alpha subunit and a response of either to exogenous thyrotropin-releasing hormone (TRH), which is available only outside the United States. Approximately 20 percent of gonadotroph adenomas will exhibit one or more of these abnormalities. (See  <a class="medical medical_review" href="/d/html/6627.html" rel="external">"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent1">Clinically silent somatotroph adenomas can often be identified by elevated serum levels of insulin-like growth factor 1 (IGF-1) [<a href="#rid5">5</a>] and clinically silent corticotroph adenomas by elevated levels of corticotropin (ACTH) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/6627.html" rel="external">"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identifying one of these biochemical markers can also be used to monitor the response to surgery and subsequent therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identifying a highly experienced pituitary surgeon. (See <a class="local">'Complications'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identifying any pituitary hormone deficiencies that need to be treated preoperatively, including hypothyroidism due to thyroid-stimulating hormone (TSH) deficiency and hypocortisolism due to corticotropin (ACTH) deficiency (<a class="graphic graphic_algorithm graphicRef120721" href="/d/graphic/120721.html" rel="external">algorithm 1</a>). Hypothyroidism, which increases the risk of respiratory insufficiency following postoperative administration of opiates or barbiturates, should be corrected preoperatively, or pain medication should be used in lower than usual doses. Hypocortisolism should be replaced physiologically.</p><p></p><p class="headingAnchor" id="H4126400346"><span class="h2">Glucocorticoid coverage</span><span class="headingEndMark"> — </span>Because of the possibility that nonadenomatous pituitary tissue could be removed inadvertently when attempting to remove the large volume of adenoma, patients should be treated with 100 mg of <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> beginning at the induction of anesthesia. The dose should be gradually decreased during the next few days. We administer a replacement dose (eg, 15 to 25 mg/day) following discharge until the initial postoperative evaluation four to six weeks after discharge (<a class="graphic graphic_algorithm graphicRef120721" href="/d/graphic/120721.html" rel="external">algorithm 1</a>).</p><p>Others recommend measuring serum cortisol on the third postoperative day, 24 hours after the previous dose of <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a>, and if the value is low (less than 5 mcg/dL [138 nmol/L]) or borderline (5 to 15 mcg/dL [138 to 469 nmol/L]), prescribing replacement hydrocortisone on discharge [<a href="#rid7">7,8</a>].</p><p>Exogenous <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> should be continued until a definitive determination of adrenal status has been made.</p><p class="headingAnchor" id="H2559547"><span class="h2">Postoperative issues</span></p><p class="headingAnchor" id="H1153646238"><span class="h3">Arginine vasopressin deficiency and SIADH</span><span class="headingEndMark"> — </span>Both arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus) and the syndrome of inappropriate antidiuretic hormone (SIADH) can occur shortly after transsphenoidal surgery. AVP-D is most likely to occur within the first two days after surgery and is usually transient but may be permanent. SIADH is most likely to occur one week afterwards and is always transient. Rarely, a "triphasic" response occurs, first AVP-D, which then remits and is followed by SIADH, which is followed by permanent AVP-D [<a href="#rid9">9,10</a>].</p><p>The possibility of these abnormalities in vasopressin secretion dictate that any patient who has transsphenoidal surgery be assessed frequently for these conditions during the first week after surgery. In the first four days after surgery, the patient should be asked about thirst, and fluid intake and output should be recorded. If AVP-D has not occurred by postoperative day 4, fluid intake should then be restricted to 1 liter/day for the next three days, and the serum sodium repeated on day 7. If the sodium is then normal, fluid restriction can end.</p><p>AVP-D that occurs in the first day after surgery, when absorption through the nasal mucosa is variable, should be treated with <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> intravenously in doses from 0.25 to 1.0 mcg every 12 to 24 hours, titrated to keep urine volume and serum sodium normal. If AVP-D has not remitted by the time of discharge, the desmopressin can be given as a nasal spray or orally. (See  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses"</a>.)</p><p>AVP-D is more common than SIADH, occurring in 18.5 percent in one series of 319 patients who underwent pituitary surgery at one institution [<a href="#rid9">9</a>] and 54.2 percent of 57 patients at another [<a href="#rid11">11</a>]. It usually occurs within the first 24 hours postoperatively and is usually transient but is sometimes permanent. In the series of 319 patients, almost 50 percent had remitted in one week and approximately 80 percent in three months [<a href="#rid9">9</a>].</p><p>SIADH occurred in 8.8 percent and 36.7 percent in the above two series [<a href="#rid9">9,11</a>]. In a third series, in which sodium was measured routinely on postoperative day 7 in 241 patients, 23 percent had asymptomatic hyponatremia and 5 percent symptomatic [<a href="#rid10">10</a>]. The mean serum sodium was 128 mmol/L in the asymptomatic patients and 120 mmol/L in the symptomatic ones.</p><p class="headingAnchor" id="H612481211"><span class="h3">First evaluation post-discharge</span><span class="headingEndMark"> — </span>Four to six weeks after discharge from the hospital, the patient should be evaluated for the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Amount of residual adenoma – A crude estimation of the amount of residual adenoma can be determined by magnetic resonance imaging (MRI), but artifacts of surgery may obscure the actual amount of residual adenoma tissue for several months. A more accurate view is provided when the artifacts of surgery have regressed three to six months later. Another estimate of the amount of residual adenoma can be made by measuring the serum concentration of any adenoma product that had been elevated before surgery, such as FSH and alpha subunit for gonadotroph adenomas, IGF-1 for clinically silent somatotroph adenomas, or ACTH for clinically silent corticotroph adenomas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Visual function (by acuity and visual fields), performed by an ophthalmologist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hormonal function of the nonadenomatous pituitary, regardless of whether it was normal or abnormal prior to surgery. This evaluation should include measurements of:</p><p></p><p class="bulletIndent1">Serum thyroxine (T4).</p><p></p><p class="bulletIndent1">Early morning serum cortisol 24 hours after the previous dose of <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> (<a class="graphic graphic_algorithm graphicRef120721" href="/d/graphic/120721.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the serum cortisol value is ≤5 mcg/dL (138 nmol/L), the patient has secondary adrenal insufficiency (ACTH deficiency).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If it is ≥15 mcg/dL (414 nmol/L), the patient has normal adrenal function, and exogenous <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> can be discontinued.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If it is between 5 and 15 mcg/dL (148 and 414 nmol/L) on a total of three occasions, a test of ACTH reserve should be performed. Most clinicians perform the cosyntropin stimulation test because of its ease of administration. However, falsely normal results are sometimes seen in patients with hypopituitarism in the first couple of weeks after pituitary surgery [<a href="#rid12">12</a>]. The author of this topic prefers the <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> stimulation test. (See  <a class="medical medical_review" href="/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum estradiol in premenopausal females with oligomenorrhea or amenorrhea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum testosterone in a male.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for growth hormone deficiency. (See  <a class="medical medical_review" href="/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism", section on 'Growth hormone'</a>.)</p><p></p><p class="headingAnchor" id="H1213382924"><span class="h1">OUTCOMES OF SURGERY</span></p><p class="headingAnchor" id="H244023969"><span class="h2">Residual adenoma</span><span class="headingEndMark"> — </span>Rates of complete adenoma removal are as low as 20 percent and as high as 65 to 75 percent, as surgical results vary widely by center and surgeon. In a meta-analysis of 58 case series of patients with nonfunctioning pituitary adenomas undergoing transsphenoidal surgery, complete removal of the adenoma, as judged by the surgeon, was achieved in only 20 percent of cases [<a href="#rid13">13</a>]. More experienced surgeons and high-volume centers have higher rates of complete removal (approximately 65 to 75 percent) [<a href="#rid14">14,15</a>].</p><p>If there is no or little discernible residual adenoma tissue by magnetic resonance imaging (MRI) following surgery, the patient should be monitored by MRI and hormonally, initially at six-month intervals. If there is considerable residual adenomatous tissue, radiation should be administered. (See <a class="local">'Adjuvant radiation therapy'</a> below.)</p><p>Long-term monitoring is necessary because the risk of adenoma regrowth is significant, particularly after surgery alone. (See <a class="local">'Long-term monitoring'</a> below.)</p><p>Lifelong management of pituitary hormone deficiencies is required in many patients. (See <a class="local">'Adjuvant radiation therapy'</a> below and <a class="local">'Hormonal abnormalities'</a> below.)</p><p class="headingAnchor" id="H1213383702"><span class="h2">Vision</span><span class="headingEndMark"> — </span>Transsphenoidal surgery improves vision in approximately 80 percent of patients [<a href="#rid3">3</a>]; improvement can be seen in the first few days after surgery [<a href="#rid16">16,17</a>]. If vision was abnormal before surgery, it should be re-evaluated a month or two afterward and less often until no further change occurs.</p><p class="headingAnchor" id="H1213383709"><span class="h2">Hormonal abnormalities</span><span class="headingEndMark"> — </span>Unlike the improvement in vision, improvement in pituitary function is less likely. Preoperatively, the majority of patients have pituitary hormone deficiencies, most commonly, growth hormone deficiency. In the meta-analysis described above, in patients with preoperative pituitary hormone abnormalities, 30 percent of patients experienced an improvement in some hormone deficiency [<a href="#rid13">13</a>]. However, most patients are left with long-term deficiencies that need replacement. In a systematic review of eight studies in over 1000 patients, the approximate frequencies of postoperative hormone deficiencies were [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Growth hormone – 83 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Luteinizing hormone (LH)/follicle-stimulating hormone (FSH) – 60 percent. Removal of the adenoma usually does not allow recovery of function of the normal gonadotroph cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid-stimulating hormone (TSH) – 30 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Corticotropin (ACTH) – 30 percent.</p><p></p><p>Although hormonal function four to six weeks after surgery usually indicates function longer term, improvement may yet occur. In 109 patients who had transsphenoidal surgery for pituitary adenomas and whose pituitary function was tested before and periodically for a year after surgery, 15 had abnormal cortisol response to cosyntropin six weeks afterwards, but five of those had a normal cortisol response 12 months afterwards [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H1213381995"><span class="h2">Complications</span><span class="headingEndMark"> — </span>In the meta-analysis described above, the mortality rate in the immediate postoperative period was 1 percent [<a href="#rid13">13</a>]. Serious complications occurred in less than 5 percent of patients and included cerebrospinal fluid leakage, fistula, meningitis, and new visual field defects.</p><p>The risk of complications is inversely proportional to the experience of the surgeon in performing transsphenoidal surgery. In one study, 958 neurosurgeons reported their own experiences in response to a questionnaire [<a href="#rid1">1</a>]. Both serious complications (such as loss of vision and death) and less serious complications (such as hormonal deficiencies) were higher among surgeons who had performed fewer transsphenoidal procedures (<a class="graphic graphic_table graphicRef68269" href="/d/graphic/68269.html" rel="external">table 1</a>). For example, among neurosurgeons who reported performing fewer than 200 transsphenoidal procedures, 1.2 percent of procedures resulted in death, but among neurosurgeons who reported performing more than 500 procedures, only 0.2 percent resulted in death.</p><p>A second study utilized a national database and found that among 825 surgeons who performed 5497 operations, the complication rate was also less among surgeons who performed more transsphenoidal procedures [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H1900485669"><span class="h2">Recurrent adenoma</span><span class="headingEndMark"> — </span>Approximately 20 percent of adenomas recur after transsphenoidal surgery alone [<a href="#rid13">13</a>]; however, the risk of recurrence is much lower if there is no MRI evidence of residual adenoma after surgery. Adjuvant radiation therapy lowers the risk of recurrence. (See <a class="local">'Adjuvant radiation therapy'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h1">ADJUVANT RADIATION THERAPY</span></p><p class="headingAnchor" id="H2647763296"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Radiation therapy is useful in preventing regrowth of residual adenoma tissue following transsphenoidal surgery. The decision whether to recommend radiation is based on the amount and location of the residual tissue by magnetic resonance imaging (MRI), the aggressiveness of the adenoma, and the patient's age and general health. The MRI is performed three to six months after surgery, when artifacts of surgery have regressed.</p><p>Radiation is also useful when there is evidence of adenoma regrowth in the months or years after surgery. Radiation therapy is usually not employed as primary therapy for gonadotroph and other clinically nonfunctioning pituitary adenomas, because its effects occur too slowly for a patient with neurologic symptoms. (See  <a class="medical medical_review" href="/d/html/86684.html" rel="external">"Radiation therapy of pituitary adenomas", section on 'Clinically nonfunctioning pituitary adenomas'</a>.)</p><p class="headingAnchor" id="H3838705385"><span class="h2">Types of radiation therapy</span><span class="headingEndMark"> — </span>Radiation therapy can be administered from a linear accelerator, which delivers photons; from a machine that delivers gamma radiation from radioactive cobalt-60; or from a cyclotron or synchrotron that delivers protons. Radiation can be delivered as a single high dose, which is sometimes referred to a "stereotactic radiosurgery," or as multiple smaller fractions, referred to as "fractionated." Each of these types of radiation can be adjusted to the geometric shape of the lesion; terms used to describe these adjustments are "stereotactic," "three-dimensional conformal," and "intensity modulated."</p><p class="headingAnchor" id="H252940313"><span class="h2">Choice of radiation type</span><span class="headingEndMark"> — </span>In deciding on the type of radiation for an individual patient, the major choice is between single high-dose radiation and fractionated radiation. The choice depends on the distance of the lesion from radiation-sensitive tissues, such as the optic chiasm, and the size of the lesion. Lesions that are only 3 to 5 mm from radiation-sensitive tissues, such as the optic chiasm, and lesions that are 30 mm or more in diameter are more safely treated by fractionated radiation.</p><p class="headingAnchor" id="H2995583681"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>Radiation appears generally effective in preventing regrowth of clinically nonfunctioning pituitary adenomas following incomplete surgical resection. No regrowth has been reported in 90 percent of patients after 5 to 10 years in patients treated by fractionated radiation from a linear accelerator [<a href="#rid20">20-24</a>] or proton source [<a href="#rid25">25</a>] or by single high-dose radiation from a gamma source or linear accelerator [<a href="#rid26">26,27</a>].</p><p class="headingAnchor" id="H497237065"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>All forms of radiation can cause delayed side effects. Hypopituitarism is relatively common, and neurologic deficits are relatively uncommon.</p><p>Pituitary hormonal deficiencies (hypoadrenalism, hypothyroidism, hypogonadism) developed in approximately one-third of the subjects in three studies of fractionated radiation during a median observation period of 40 or more months [<a href="#rid23">23-25</a>]. In a multicenter study of single, high-dose gamma radiation, 86 of 410 patients with clinically nonfunctioning adenomas developed pituitary hormonal deficiencies in a median follow-up time of 51 months [<a href="#rid28">28</a>]. The actuarial rates of hypopituitarism were 7.8, 22.4, and 31.3 percent at 1, 5, and 10 years, respectively.</p><p>Neurologic deficits occur less commonly but are more serious. In a review of 35 studies that involved 1621 patients (452 with clinically nonfunctioning adenomas) treated with single-dose radiation from a linear accelerator, gamma source, or proton source, in which the median period of observation was &lt;40 months in approximately one-half and &gt;40 months in approximately one-half, optic neuropathy in approximately 1 percent, other cranial neuropathies occurred in approximately 1.3 percent, and parenchymal brain damage (in the hypothalamus and temporal lobe) occurred in approximately 0.8 percent [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H4007841830"><span class="h1">LONG-TERM MONITORING</span><span class="headingEndMark"> — </span>Long-term monitoring should include testing every 6 to 12 months initially to detect growth of residual adenoma tissue and the adequacy of hormonal replacement.</p><p class="headingAnchor" id="H1933086427"><span class="h2">Adenoma regrowth</span><span class="headingEndMark"> — </span>Evaluation for adenoma regrowth should include measurement of whatever serum marker was elevated before surgery and magnetic resonance imaging (MRI); if there is no regrowth after a year or two, the interval between scans can be lengthened. Early detection permits appropriate use of radiation therapy to minimize the need for repeat surgery. If MRI six months after transsphenoidal surgery shows little adenoma tissue or the residual tissue is not in a location of clinical significance, we recommend observation only by MRI, initially yearly.</p><p>The frequency of regrowth of residual adenoma tissue varies but is more likely when a patient does not have radiotherapy [<a href="#rid13">13</a>]. In one report of 91 patients with nonfunctioning pituitary macroadenomas who underwent surgery but who did not have radiotherapy afterwards, adenoma regrowth occurred in 10 percent of patients; the mean time to adenoma regrowth was approximately six years [<a href="#rid29">29</a>]. In two other series, of 491 and 159 patients, the recurrence rates were higher, 19 and 34 percent [<a href="#rid14">14,30</a>].</p><p>Not surprisingly, patients who have suprasellar extension of an adenoma are at higher risk for recurrence following surgery [<a href="#rid30">30,31</a>]. Radiation therapy reduces this risk but is associated with long-term morbidity and should not be used routinely. (See <a class="local">'Adjuvant radiation therapy'</a> above.)</p><p class="headingAnchor" id="H2911020619"><span class="h2">Quality of life</span><span class="headingEndMark"> — </span>Quality of life has been reported to be reduced after long-term cure of functioning pituitary adenomas [<a href="#rid32">32,33</a>]. Patients with nonfunctioning pituitary macroadenomas treated successfully by transsphenoidal surgery alone or combined with radiotherapy also have impaired quality of life when compared with age-matched, healthy controls [<a href="#rid34">34</a>]. In addition, patients commonly experience increased fatigue and daytime somnolence [<a href="#rid35">35</a>]. The impaired quality of life and fatigue appear to be due to the underlying hypopituitarism [<a href="#rid33">33</a>], as well as impaired sleep quality and abnormal distribution of sleep stages [<a href="#rid36">36</a>]. Postoperative replacement of deficient hormones helps to improve quality of life, but other measures may be needed as well [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H246611097"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H1596902456"><span class="h2">Aggressive tumors</span><span class="headingEndMark"> — </span>Although most clinically nonfunctioning pituitary adenomas causing symptoms are readily treated by surgery alone or surgery followed by radiation, a very small number are unusually aggressive. These require consultation with an oncologist for consideration of chemotherapy. <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">Temozolomide</a> is the one chemotherapeutic agent that has been shown to have some benefit in treating aggressive pituitary adenomas. A review done in connection with development of clinical guidelines for management of aggressive pituitary tumors by the European Society of Endocrinology reported that in 11 studies, temozolomide reduced tumor volume in 47 percent of 106 patients [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H3223011590"><span class="h2">Asymptomatic adenomas</span><span class="headingEndMark"> — </span>Gonadotroph and other clinically nonfunctioning adenomas that are asymptomatic and not an immediate threat to vision do not require surgery, although hormonal deficiencies should be treated and re-evaluation of adenoma size and pituitary function should be performed at yearly intervals.</p><p>This situation is increasingly common because an increasing number of these adenomas are detected as incidental findings when magnetic resonance imaging (MRI) is performed for other reasons, such as head trauma. (See  <a class="medical medical_review" href="/d/html/6642.html" rel="external">"Pituitary incidentalomas"</a>.)</p><p>Only limited data are available on the natural history of nonfunctioning macroadenomas because many patients who have them undergo surgery. However, in studies that have monitored growth of these adenomas for more than four to five years, approximately 50 percent of patients experienced adenoma growth [<a href="#rid3">3,39-41</a>]. Thus, although watchful waiting may be appropriate in some cases, long-term follow-up is necessary as adenoma growth can be anticipated in 50 percent.</p><p>In a small percent of cases, nonfunctioning adenomas may spontaneously regress. In a review of 10 series, this occurred in 34 of 304 patients (11 percent) [<a href="#rid3">3</a>], while in an individual series of 37 patients with five years of follow-up, four experienced pituitary apoplexy [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H11"><span class="h1">THERAPIES NOT RECOMMENDED</span><span class="headingEndMark"> — </span>The extraordinary success of dopamine agonists in reducing the size of, as well as secretion by, lactotroph adenomas has prompted attempts to find a pharmacologic treatment for gonadotroph adenomas (see  <a class="medical medical_review" href="/d/html/6630.html" rel="external">"Management of hyperprolactinemia"</a>). To date, however, <strong>no drug</strong> has been found that consistently and substantially reduces the size of gonadotroph adenomas.</p><p><a class="drug drug_general" data-topicid="9164" href="/d/drug information/9164.html" rel="external">Bromocriptine</a> therapy for nonfunctioning adenomas has been disappointing [<a href="#rid3">3</a>]; <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> may have some effect [<a href="#rid42">42</a>]. However, data are limited, and this drug should not be considered an alternative to surgery. The cell membranes of some clinically nonfunctioning pituitary adenomas have somatostatin receptors [<a href="#rid43">43,44</a>], so two groups have administered <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> (a somatostatin analog) to such patients. One group found improvement in visual fields in three of four patients, but no decrease in adenoma size [<a href="#rid45">45</a>]. The other group found decreases in serum alpha subunit values in three of six patients and a reduction in adenoma size and visual impairment in two each; there was, however, no correlation among the three measurements [<a href="#rid46">46</a>].</p><p>Gonadotropin-releasing hormone (GnRH) agonists and antagonists have been studied as potential therapies for gonadotroph-secreting adenomas; both are ineffective. Administration of the GnRH antagonist, Nal-Glu GnRH, for six months to men with gonadotroph adenomas normalized their high serum follicle-stimulating hormone (FSH) concentrations but did not decrease the size of their adenomas [<a href="#rid47">47</a>], suggesting that FSH secretion by gonadotroph adenomas, but not adenoma size, is dependent upon endogenous GnRH. Administration of GnRH agonist analogs to patients with gonadotroph adenomas usually has either an agonist effect or no change in gonadotropin secretion and does not affect adenoma size [<a href="#rid48">48-50</a>].</p><p class="headingAnchor" id="H2426217207"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116762.html" rel="external">"Society guideline links: Pituitary tumors and hypopituitarism"</a>.)</p><p class="headingAnchor" id="H14470905"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/82820.html" rel="external">"Patient education: Pituitary adenoma (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transsphenoidal surgery</strong> – In patients with gonadotroph or other clinically nonfunctioning pituitary adenomas that are large enough to cause neurologic symptoms, such as visual field abnormalities, we recommend transsphenoidal surgery as initial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). The choice of surgical procedure, microscopic or endoscopic, depends upon the neurosurgeon's experience. (See <a class="local">'Initial therapy: Transsphenoidal surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery versus waiting</strong> –<strong> </strong>For patients who have extrasellar extension but do not have neurologic symptoms, we discuss the risks of surgery versus the risks of waiting. For example, an adenoma that is markedly elevating the optic chiasm is very likely to begin to cause visual abnormalities in the next few years, yet some patients will choose to wait until that occurs. These patients should be followed by magnetic resonance imaging (MRI) and visual field examinations every 6 to 12 months. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perioperative issues</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preoperative hormonal deficiencies</strong> – Hormonal deficiencies due to impaired function of the nonadenomatous pituitary should be replaced. Whatever treatment is used, lifetime re-evaluation is needed. (See <a class="local">'Preoperative preparation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoid coverage</strong> – <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">Hydrocortisone</a> should be administered in high doses during surgery and doses gradually decreasing to replacement within a few days. (See <a class="local">'Glucocorticoid coverage'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SIADH and AVP-D</strong> – For patients who undergo surgery, daily postoperative monitoring for arginine vasopressin deficiency (AVP-D) should be performed until discharge and monitoring for syndrome of inappropriate antidiuretic hormone (SIADH) at one week afterwards.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative evaluation</strong> – Four to six weeks post-discharge, the patient should again be evaluated for residual adenoma, hypocortisolism, hypothyroidism, hypogonadism, and AVP-D. In addition, the patient should be evaluated for visual function and all other hormonal functions of the nonadenomatous pituitary (<a class="graphic graphic_algorithm graphicRef120721" href="/d/graphic/120721.html" rel="external">algorithm 1</a>). (See <a class="local">'Postoperative issues'</a> above and <a class="local">'First evaluation post-discharge'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Residual adenoma</strong> – If little or no residual adenoma tissue remains 6 to 12 months after surgery or if a larger amount remains but does not threaten neurologic complications, we suggest monitoring the residual tissue with MRI. (See <a class="local">'Residual adenoma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adjuvant radiation therapy</strong> – If the residual tissue grows progressively, we suggest adjuvant radiation therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Administration of radiation stereotactically should now be used exclusively. (See <a class="local">'Adjuvant radiation therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Long-term monitoring</strong> – Long-term monitoring should include assessment every 6 to 12 months initially to detect growth of residual adenoma tissue and the adequacy of hormonal replacement. (See <a class="local">'Long-term monitoring'</a> above.)</p><p></p><p class="bulletIndent2">Evaluation for adenoma regrowth should include measurement of whatever serum marker was elevated before surgery and an MRI; if there is no regrowth after a year or two, the interval between scans can be lengthened.</p><p></p><p class="bulletIndent2">Hormonal hypersecretion by the adenoma preoperatively, when it occurs, can be used to monitor the effects of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic macroadenomas</strong> – For macroadenomas that are not causing visual symptoms, we suggest yearly monitoring of pituitary function and adenoma size (MRI). (See <a class="local">'Asymptomatic adenomas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aggressive tumors</strong> – Although most clinically nonfunctioning pituitary adenomas causing symptoms are readily treated by surgery alone or surgery followed by radiation, a very small number are unusually aggressive. These require consultation with an oncologist for consideration of chemotherapy. (See <a class="local">'Aggressive tumors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 1997; 40:225.</a></li><li><a class="nounderline abstract_t">Wilson CB. Surgical management of pituitary tumors. J Clin Endocrinol Metab 1997; 82:2381.</a></li><li><a class="nounderline abstract_t">Dekkers OM, Pereira AM, Romijn JA. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 2008; 93:3717.</a></li><li><a class="nounderline abstract_t">Cote DJ, Smith TR, Sandler CN, et al. Functional Gonadotroph Adenomas: Case Series and Report of Literature. Neurosurgery 2016; 79:823.</a></li><li><a class="nounderline abstract_t">Wade AN, Baccon J, Grady MS, et al. Clinically silent somatotroph adenomas are common. Eur J Endocrinol 2011; 165:39.</a></li><li><a class="nounderline abstract_t">Guttenberg KB, Mayson SE, Sawan C, et al. Prevalence of clinically silent corticotroph macroadenomas. Clin Endocrinol (Oxf) 2016; 85:874.</a></li><li><a class="nounderline abstract_t">Inder WJ, Hunt PJ. Glucocorticoid replacement in pituitary surgery: guidelines for perioperative assessment and management. J Clin Endocrinol Metab 2002; 87:2745.</a></li><li><a class="nounderline abstract_t">Ausiello JC, Bruce JN, Freda PU. Postoperative assessment of the patient after transsphenoidal pituitary surgery. Pituitary 2008; 11:391.</a></li><li><a class="nounderline abstract_t">Adams JR, Blevins LS Jr, Allen GS, et al. Disorders of water metabolism following transsphenoidal pituitary surgery: a single institution's experience. Pituitary 2006; 9:93.</a></li><li><a class="nounderline abstract_t">Zada G, Liu CY, Fishback D, et al. Recognition and management of delayed hyponatremia following transsphenoidal pituitary surgery. J Neurosurg 2007; 106:66.</a></li><li><a class="nounderline abstract_t">Kristof RA, Rother M, Neuloh G, Klingmüller D. Incidence, clinical manifestations, and course of water and electrolyte metabolism disturbances following transsphenoidal pituitary adenoma surgery: a prospective observational study. J Neurosurg 2009; 111:555.</a></li><li><a class="nounderline abstract_t">Streeten DH, Anderson GH Jr, Bonaventura MM. The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test. J Clin Endocrinol Metab 1996; 81:285.</a></li><li><a class="nounderline abstract_t">Murad MH, Fernández-Balsells MM, Barwise A, et al. Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2010; 73:777.</a></li><li><a class="nounderline abstract_t">Losa M, Mortini P, Barzaghi R, et al. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 2008; 108:525.</a></li><li><a class="nounderline abstract_t">Messerer M, De Battista JC, Raverot G, et al. Evidence of improved surgical outcome following endoscopy for nonfunctioning pituitary adenoma removal. Neurosurg Focus 2011; 30:E11.</a></li><li><a class="nounderline abstract_t">Kerrison JB, Lynn MJ, Baer CA, et al. Stages of improvement in visual fields after pituitary tumor resection. Am J Ophthalmol 2000; 130:813.</a></li><li><a class="nounderline abstract_t">Jakobsson KE, Petruson B, Lindblom B. Dynamics of visual improvement following chiasmal decompression. Quantitative pre- and postoperative observations. Acta Ophthalmol Scand 2002; 80:512.</a></li><li><a class="nounderline abstract_t">Pofi R, Gunatilake S, Macgregor V, et al. Recovery of the Hypothalamo-Pituitary-Adrenal Axis After Transsphenoidal Adenomectomy for Non-ACTH-Secreting Macroadenomas. J Clin Endocrinol Metab 2019; 104:5316.</a></li><li><a class="nounderline abstract_t">Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003; 88:4709.</a></li><li><a class="nounderline abstract_t">Paek SH, Downes MB, Bednarz G, et al. Integration of surgery with fractionated stereotactic radiotherapy for treatment of nonfunctioning pituitary macroadenomas. Int J Radiat Oncol Biol Phys 2005; 61:795.</a></li><li><a class="nounderline abstract_t">Pollock BE, Cochran J, Natt N, et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys 2008; 70:1325.</a></li><li><a class="nounderline abstract_t">Pamir MN, Kiliç T, Belirgen M, et al. Pituitary adenomas treated with gamma knife radiosurgery: volumetric analysis of 100 cases with minimum 3 year follow-up. Neurosurgery 2007; 61:270.</a></li><li><a class="nounderline abstract_t">Colin P, Jovenin N, Delemer B, et al. Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients. Int J Radiat Oncol Biol Phys 2005; 62:333.</a></li><li><a class="nounderline abstract_t">Mackley HB, Reddy CA, Lee SY, et al. Intensity-modulated radiotherapy for pituitary adenomas: the preliminary report of the Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007; 67:232.</a></li><li><a class="nounderline abstract_t">Ronson BB, Schulte RW, Han KP, et al. Fractionated proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys 2006; 64:425.</a></li><li><a class="nounderline abstract_t">Sheehan JP, Niranjan A, Sheehan JM, et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 2005; 102:678.</a></li><li><a class="nounderline abstract_t">Mingione V, Yen CP, Vance ML, et al. Gamma surgery in the treatment of nonsecretory pituitary macroadenoma. J Neurosurg 2006; 104:876.</a></li><li><a class="nounderline abstract_t">Cordeiro D, Xu Z, Mehta GU, et al. Hypopituitarism after Gamma Knife radiosurgery for pituitary adenomas: a multicenter, international study. J Neurosurg 2018.</a></li><li><a class="nounderline abstract_t">Dekkers OM, Pereira AM, Roelfsema F, et al. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2006; 91:1796.</a></li><li><a class="nounderline abstract_t">O'Sullivan EP, Woods C, Glynn N, et al. The natural history of surgically treated but radiotherapy-naïve nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf) 2009; 71:709.</a></li><li><a class="nounderline abstract_t">Chang EF, Zada G, Kim S, et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 2008; 108:736.</a></li><li><a class="nounderline abstract_t">Biermasz NR, van Thiel SW, Pereira AM, et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 2004; 89:5369.</a></li><li><a class="nounderline abstract_t">van Aken MO, Pereira AM, Biermasz NR, et al. Quality of life in patients after long-term biochemical cure of Cushing's disease. J Clin Endocrinol Metab 2005; 90:3279.</a></li><li><a class="nounderline abstract_t">Dekkers OM, van der Klaauw AA, Pereira AM, et al. Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2006; 91:3364.</a></li><li><a class="nounderline abstract_t">van der Klaauw AA, Biermasz NR, Pereira AM, et al. Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls. Clin Endocrinol (Oxf) 2008; 69:769.</a></li><li><a class="nounderline abstract_t">Biermasz NR, Joustra SD, Donga E, et al. Patients previously treated for nonfunctioning pituitary macroadenomas have disturbed sleep characteristics, circadian movement rhythm, and subjective sleep quality. J Clin Endocrinol Metab 2011; 96:1524.</a></li><li><a class="nounderline abstract_t">Andela CD, Lobatto DJ, Pereira AM, et al. How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review. Pituitary 2018; 21:208.</a></li><li><a class="nounderline abstract_t">Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 2018; 178:G1.</a></li><li><a class="nounderline abstract_t">Arita K, Tominaga A, Sugiyama K, et al. Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J Neurosurg 2006; 104:884.</a></li><li><a class="nounderline abstract_t">Dekkers OM, Hammer S, de Keizer RJ, et al. The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol 2007; 156:217.</a></li><li><a class="nounderline abstract_t">Karavitaki N, Collison K, Halliday J, et al. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf) 2007; 67:938.</a></li><li><a class="nounderline abstract_t">Greenman Y, Tordjman K, Osher E, et al. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol (Oxf) 2005; 63:39.</a></li><li><a class="nounderline abstract_t">Ikuyama S, Nawata H, Kato K, et al. Specific somatostatin receptors on human pituitary adenoma cell membranes. J Clin Endocrinol Metab 1985; 61:666.</a></li><li><a class="nounderline abstract_t">Reubi JC, Heitz PU, Landolt AM. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J Clin Endocrinol Metab 1987; 65:65.</a></li><li><a class="nounderline abstract_t">de Bruin TW, Kwekkeboom DJ, Van't Verlaat JW, et al. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 1992; 75:1310.</a></li><li><a class="nounderline abstract_t">Katznelson L, Oppenheim DS, Coughlin JF, et al. Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors. J Clin Endocrinol Metab 1992; 75:1318.</a></li><li><a class="nounderline abstract_t">Daneshdoost L, Pavlou SN, Molitch ME, et al. Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 1990; 71:92.</a></li><li><a class="nounderline abstract_t">Roman SH, Goldstein M, Kourides IA, et al. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor. J Clin Endocrinol Metab 1984; 58:313.</a></li><li><a class="nounderline abstract_t">Sassolas G, Lejeune H, Trouillas J, et al. Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1988; 67:180.</a></li><li><a class="nounderline abstract_t">Klibanski A, Jameson JL, Biller BM, et al. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors. J Clin Endocrinol Metab 1989; 68:81.</a></li></ol></div><div id="topicVersionRevision">Topic 6631 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9007854" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253304" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Surgical management of pituitary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18682516" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26692108" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Functional Gonadotroph Adenomas: Case Series and Report of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493729" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinically silent somatotroph adenomas are common.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27346850" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of clinically silent corticotroph macroadenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12050244" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Glucocorticoid replacement in pituitary surgery: guidelines for perioperative assessment and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18320327" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Postoperative assessment of the patient after transsphenoidal pituitary surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16832585" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Disorders of water metabolism following transsphenoidal pituitary surgery: a single institution's experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17236489" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Recognition and management of delayed hyponatremia following transsphenoidal pituitary surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19199508" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Incidence, clinical manifestations, and course of water and electrolyte metabolism disturbances following transsphenoidal pituitary adenoma surgery: a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8550765" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846296" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18312100" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21456922" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evidence of improved surgical outcome following endoscopy for nonfunctioning pituitary adenoma removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11124302" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Stages of improvement in visual fields after pituitary tumor resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390163" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dynamics of visual improvement following chiasmal decompression. Quantitative pre- and postoperative observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31225871" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Recovery of the Hypothalamo-Pituitary-Adrenal Axis After Transsphenoidal Adenomectomy for Non-ACTH-Secreting Macroadenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557445" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708259" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Integration of surgery with fractionated stereotactic radiotherapy for treatment of nonfunctioning pituitary macroadenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18029107" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17762739" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pituitary adenomas treated with gamma knife radiosurgery: volumetric analysis of 100 cases with minimum 3 year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15890572" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17084541" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intensity-modulated radiotherapy for pituitary adenomas: the preliminary report of the Cleveland Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16257131" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fractionated proton beam irradiation of pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15871511" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16776330" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Gamma surgery in the treatment of nonsecretory pituitary macroadenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31369225" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hypopituitarism after Gamma Knife radiosurgery for pituitary adenomas: a multicenter, international study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507632" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19302582" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The natural history of surgically treated but radiotherapy-naïve nonfunctioning pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18377253" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15531483" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741267" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Quality of life in patients after long-term biochemical cure of Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16787991" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18435832" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367934" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Patients previously treated for nonfunctioning pituitary macroadenomas have disturbed sleep characteristics, circadian movement rhythm, and subjective sleep quality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29302835" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29046323" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16776331" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287411" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The natural course of non-functioning pituitary macroadenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17692109" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : What is the natural history of nonoperated nonfunctioning pituitary adenomas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963059" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2863281" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Specific somatostatin receptors on human pituitary adenoma cell membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3034958" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1430093" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1358910" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2115048" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a gonadotropin-releasing hormone antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6198331" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2967850" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2535852" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
